Aligos Therapeutics (ALGS) EBT Margin (2021 - 2026)
Aligos Therapeutics (ALGS) reported EBT Margin of 802.93% for Q1 2026, down 1467142.0% on a YoY basis from N/an in Q1 2025, and up 93.16% quarter-over-quarter from 11746.15% in Q4 2025.
Aligos Therapeutics (ALGS) EBT Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics has reported EBT Margin for 6 years, with the latest figure at 802.93% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 1467142.0% year-over-year to 802.93%; the trailing twelve-month figure through Mar 2026 stood at 1907.18% (down 26809.0% YoY), and the FY2025 full-year result was 1092.36%, up 253212.0% from the prior year.
- EBT Margin for Q1 2026 stood at 802.93%, up from 11746.15% in the prior quarter.
- The five-year high for EBT Margin was 13868.49% in Q1 2025, with the low at 13551.65% in Q4 2024.
- Historically, EBT Margin has averaged 1935.94% across 5 years, with a median of 887.19% in 2023.
- Annual changes were most pronounced in 2025 — EBT Margin surged 1888852 bps — and 2026, when it slumped 1467142 bps.
- Aligos Therapeutics' EBT Margin stood at 617.39% in 2022, then retreated by 18 bps to 731.13% in 2023, then tumbled by 1754 bps to 13551.65% in 2024, then increased by 13 bps to 11746.15% in 2025, then soared by 93 bps to 802.93% in 2026.
- The last three EBT Margin figures came in at 802.93% (Q1 2026), 11746.15% (Q4 2025), and 4248.45% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -802.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -802.93% |
| Dec 31, 2025 | -11,746.15% |
| Sep 30, 2025 | -4,248.45% |
| Jun 30, 2025 | -1,624.66% |
| Mar 31, 2025 | 13,868.49% |
| Dec 31, 2024 | -13,551.65% |
| Sep 30, 2024 | -1,533.44% |
| Jun 30, 2024 | 494.82% |
| Mar 31, 2024 | -5,020.03% |
| Dec 31, 2023 | -731.13% |
| Sep 30, 2023 | -836.21% |
| Jun 30, 2023 | -419.98% |
| Mar 31, 2023 | -887.19% |
| Dec 31, 2022 | -617.39% |
| Mar 31, 2022 | -1,383.20% |
| Dec 31, 2021 | -10,292.10% |
| Sep 30, 2021 | -2,146.91% |
| Jun 30, 2021 | -1,928.16% |
| Mar 31, 2021 | -3,036.15% |